News
The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.
Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...
The company says broad tariffs would raise costs, limit patient access and undermine domestic manufacturing. Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would ...
The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...
Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo’s main rival in the GLP-1RA arena, Eli ...
Competition among the makers of weight loss treatments is intensifying.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results